<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40967296</PMID><DateRevised><Year>2025</Year><Month>09</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-6744</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Sep</Month><Day>16</Day></PubDate></JournalIssue><Title>American heart journal</Title><ISOAbbreviation>Am Heart J</ISOAbbreviation></Journal><ArticleTitle>Risk-Guided Disease Management To Prevent Heart Failure In Adult Cancer Survivors of Previous Cardiotoxic Cancer Treatments: Baseline Results of the REDEEM Trial.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S0002-8703(25)00331-X</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ahj.2025.09.009</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Adult cancer survivors are at increased risk of heart failure (HF) due to standard risk factors and cancer treatment-related cardiac dysfunction. However, the prevalence and treatment of subclinical/stage B heart failure (SBHF) in this population are not well defined.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The REDEEM (Risk-guided Disease managEment plan to prevEnt heart failure in patients treated with previous cardiotoxic cancer treatMents) trial will evaluate HF screening and targeted intervention in long-term cancer survivors.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Survivors &#x2265;40 years old, &#x2265;5 years post potentially-cardiotoxic therapy, and with &#x2265;1 HF risk factor were screened by echocardiography for SBHF (abnormal global longitudinal shortening [GLS], left ventricular hypertrophy [LVH], diastolic dysfunction or abnormal 3-dimensional left ventricular ejection fraction [3D-LVEF]). Those with SBHF were randomized to multi-disciplinary cardio-oncology disease management plan (CO-DMP), including neurohormonal blockade, exercise training and risk factor optimization, or usual care. The primary endpoint is change in cardiorespiratory fitness (VO<sub>2</sub>peak) over 6 months.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 1,124 survivors screened, 604 underwent echocardiography, and 145 (24%) had SBHF (age 68&#xb1;18 years; 81% women). Of those eligible for randomization, 64% had breast cancer and 35% had hematological malignancy. Although baseline 3D-LVEF was preserved (52.8&#xb1;6.8%), subclinical LV dysfunction was common (GLS 15.6&#xb1;2.1%) and 39% had evidence of functional impairment (VO<sub>2</sub>peak&#x2264;18ml/kg/min<sup>-1</sup>). Abnormal GLS was associated with age, BMI, diabetes and anthracycline exposure, whereas functional impairment was only associated with age. Abnormal GLS and functional impairment were not significantly associated (OR 0.90 [95% CI 0.72-1.11], p=0.360).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Risk-based screening can identify a high-risk subpopulation of cancer survivors with SBHF.</AbstractText><AbstractText Label="REGISTRATION" NlmCategory="BACKGROUND">ClinicalTrials.gov NCT04962711, https://www.</AbstractText><AbstractText Label="CLINICALTRIALS" NlmCategory="RESULTS">gov/study/NCT04962711.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025. Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Joshua</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Baker Heart and Diabetes Institute, Melbourne, Australia; Department of Cardiometabolic Health, University of Melbourne, Melbourne, Australia; Peter MacCallum Cancer Centre, Melbourne, Australia; Royal Melbourne Hospital, Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Joel</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Baker Heart and Diabetes Institute, Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soh</LastName><ForeName>Cheng Hwee</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Baker Heart and Diabetes Institute, Melbourne, Australia; Department of Cardiometabolic Health, University of Melbourne, Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Howden</LastName><ForeName>Erin</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Baker Heart and Diabetes Institute, Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Talbot</LastName><ForeName>Jack S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Baker Heart and Diabetes Institute, Melbourne, Australia; Department of Cardiometabolic Health, University of Melbourne, Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nolan</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Baker Heart and Diabetes Institute, Melbourne, Australia; Peter MacCallum Cancer Centre, Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Whitmore</LastName><ForeName>Kristyn</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Menzies Institute for Medical Research, Hobart, Tasmania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wright</LastName><ForeName>Leah</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Baker Heart and Diabetes Institute, Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sherriff</LastName><ForeName>Ashleigh-Georgia</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>Baker Heart and Diabetes Institute, Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sivaraj</LastName><ForeName>Eswar</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Menzies Institute for Medical Research, Hobart, Tasmania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wheeler</LastName><ForeName>Greg</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Peter MacCallum Cancer Centre, Melbourne, Australia; The Sir Peter MacCallum Department of Oncology, University of Melbourne.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wiltshire</LastName><ForeName>Kirsty</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Peter MacCallum Cancer Centre, Melbourne, Australia; The Sir Peter MacCallum Department of Oncology, University of Melbourne.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Campbell</LastName><ForeName>Phillip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Barwon Health, Geelong, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramkumar</LastName><ForeName>Satish</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Victorian Heart Hospital, Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tam</LastName><ForeName>Constantine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Alfred Health, Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marwick</LastName><ForeName>Thomas H</ForeName><Initials>TH</Initials><AffiliationInfo><Affiliation>Baker Heart and Diabetes Institute, Melbourne, Australia; Department of Cardiometabolic Health, University of Melbourne, Melbourne, Australia; Menzies Institute for Medical Research, Hobart, Tasmania. Electronic address: tom.marwick@baker.edu.au.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04962711</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am Heart J</MedlineTA><NlmUniqueID>0370465</NlmUniqueID><ISSNLinking>0002-8703</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Survivorship</Keyword><Keyword MajorTopicYN="N">heart failure</Keyword><Keyword MajorTopicYN="N">screening</Keyword></KeywordList><CoiStatement>Declaration of competing interest There are no relevant conflicts of interest</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>7</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>9</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>9</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>19</Day><Hour>0</Hour><Minute>36</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>19</Day><Hour>0</Hour><Minute>36</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>18</Day><Hour>19</Hour><Minute>11</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40967296</ArticleId><ArticleId IdType="doi">10.1016/j.ahj.2025.09.009</ArticleId><ArticleId IdType="pii">S0002-8703(25)00331-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>